BridgeBio Pharma, Inc. (BBIO) Form 8-K — Aug 10, 2026

$BBIOForm 8-KItems 2.02, 9.01Filed Aug 10, 2026, 4:03 PM ET0001743881-26-000026Original filing

BridgeBio Pharma reported second quarter 2026 total revenues of $243.7 million, up from $110.6 million in the year-ago quarter, driven primarily by $222.4 million of U.S. Attruby net product revenue as physicians increasingly start treatment-naive patients on the drug. Net loss attributable to common stockholders narrowed to $152.2 million, or $0.78 per share, from $181.9 million, or $0.95 per share, in Q2 2025, and cash, cash equivalents and marketable securities totaled $720.2 million at June 30, 2026 — before counting the $1 billion preferred equity financing led by Sixth Street with participation from HealthCare Royalty (a KKR affiliate) that closed July 1, 2026.

Key figures

Revenue: 243676000
Revenue Yoy: +120% (Q2 2026 $243.7M vs Q2 2025 $110.6M; filing states a $133.1M increase)
Total Assets: 1217299000
Cash Position: 720160000
Pdufa BBP418: November 27, 2026
Rnd Expense Q2: 149448000
Sga Expense Q2: 186261000
Pdufa Encaleret: May 8, 2027
Royalty Revenue Q2: 15432000
Six Month Total Revenue: 438191000
Adh1 Patients Identified: more than 2,200 (~70 new diagnoses/month)
Six Month Attruby Revenue: 403036000
Weighted Average Shares Q2: 195785884
Total Operating Expenses Q2: 350755000
Attruby Net Product Revenue Q2: 222440000
Deferred Royalty Obligations: 879374000
License And Services Revenue Q2: 5804000
Rwe Hospitalization Reduction: 34% (p=0.002)
Proceeds From2033 Notes H1 2026: 632500000
Rwe Composite CVEvent Reduction: 37% (p=0.002)
Common Stock Repurchases H1 2026: 210003000
Noncash Interest On Deferred Royalties Q2: 41345000
Preferred Equity Financing Closed July1 2026: 1000000000

Price after filing

1 day: 0.0%7 days: -5.4%30 days: -11.5%

Close on the filing date to close N calendar days later (from $84.48). Historical, not a forecast.

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.